SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.96
+0.26 (+0.59%)
At close: 4:02PM EST

43.96 +0.01 (0.02%)
After hours: 4:02PM EST

Stock chart is not supported by your current browser
Previous Close43.70
Open43.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range43.82 - 44.05
52 Week Range38.45 - 50.65
Volume835,238
Avg. Volume1,233,040
Market Cap109.827B
Beta0.78
PE Ratio (TTM)10.47
EPS (TTM)4.20
Earnings DateN/A
Forward Dividend & Yield1.64 (3.79%)
Ex-Dividend Date2017-05-11
1y Target Est49.50
Trade prices are not sourced from all markets
  • Sanofi's Pointeau on China Strategy, Partnerships
    Bloomberg Video6 days ago

    Sanofi's Pointeau on China Strategy, Partnerships

    Dec.07 -- Jean-Christophe Pointeau, China country chair at Sanofi, discusses the changes in the Chinese health market, his business strategy in China, his partnerships and the automation of the industry. He speaks on "Bloomberg Markets: Asia" from the Fortune Global Forum in Guangzhou.

  • Philippines shuts down sale of 'risky' dengue vaccine
    Reuters Videos8 days ago

    Philippines shuts down sale of 'risky' dengue vaccine

    A public health scandal escalates in the Philippines. Manila is halting the sale of Dengvaxia after a warning that the dengue vaccine might not be safe. Reuters' Eve Johnson reports on who is now finding themselves in the public crosshairs.

  • CNW Group8 hours ago

    The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

    The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

  • TheStreet.com11 hours ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks12 hours ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Reuters15 hours ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters15 hours ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • PR Newswireyesterday

    FDA Approves Sanofi's Admelog® (insulin lispro injection)

    PARIS, Dec. 11, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sanofi's Admelog®, the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. "Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes.

  • Reutersyesterday

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reutersyesterday

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • GlobeNewswireyesterday

    FDA Approves Sanofi's Admelog® (insulin lispro injection)

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA Approves Sanofi`s Admelog ® (insulin lispro injection) First FDA-approved follow-on mealtime insulin Admelog (insulin lispro injection) 100 ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Foolyesterday

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks2 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks4 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

  • Market Realist4 days ago

    How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

    In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.

  • Philippines wants money back from Sanofi for dengue vaccine
    Associated Press5 days ago

    Philippines wants money back from Sanofi for dengue vaccine

    MANILA, Philippines (AP) — The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.

  • Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
    Zacks5 days ago

    Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

    FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

  • Reuters5 days ago

    Philippines to seek refund of $59 million from Sanofi amid vaccine risk

    The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases. "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday. The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia.

  • Business Wire6 days ago

    Sanofi explores combination treatments for multiple myeloma in new late-stage trials

    Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia.

  • Flu cases double as experts worry this season could be particularly bad
    CNBC6 days ago

    Flu cases double as experts worry this season could be particularly bad

    Experts worry this year's flu shot may not be as effective as it usually is.

  • Reuters7 days ago

    France advised against Sanofi's dengue drug for its territories

    A public body close to France's health ministry last year advised against the use of a dengue vaccine in the country's overseas territories that is currently at the centre of a health scare, regulatory documents show. Concerns surrounding the vaccine, sold by French drugmaker Sanofi under the brand Dengvaxia, have prompted the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children.

  • Sanofi's Toujeo Meets Key Objective in Head-to-Head Study
    Zacks7 days ago

    Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

    Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

  • Reuters8 days ago

    Severe dengue vaccine risk in uninfected '2 in a 1,000' -Sanofi

    French drugmaker Sanofi said on Tuesday the risk of severe dengue occurring in previously uninfected people given its Dengvaxia dengue vaccine was around two in 1,000 and these individuals recovered with treatment. The vaccine is at a centre of a safety row after new data showed it could worsen dengue in some cases, prompting the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children. Answering criticism about delays in reporting problems, Sanofi said it had only been able to conduct a detailed analysis to determine the impact of previous dengue infection this year, after co-developing a new assay with the University of Pittsburgh.

  • Reuters8 days ago

    Trial results of Zika vaccine Sanofi dropped show promise

    A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday. In February 2016, the World Health Organization declared the Zika outbreak in Brazil and elsewhere an international public health emergency because of the link between the virus and severe birth defects, touching off a scramble for a vaccine. The ZPIV vaccine, made from inactivated Zika virus particles, was developed by U.S. Army researchers, who in July 2016 had agreed to give Sanofi an exclusive license to complete testing and bring the product to market.

  • Reuters8 days ago

    Trouble mounts for Sanofi dengue vaccine over safety concerns

    The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases. The safety fears involve possible increased risk to people who had not previously been exposed to the dengue virus prior to vaccination with Dengvaxia. Dengvaxia, the first approved Dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales.